Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00011297 · ClinicalTrials.gov registry record · Phase 2
Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal
A Phase 2 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00011297 is a Phase 2 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 160 participants.
The verdict
NCT00011297, a Phase 2 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This study will evaluate a safe and useful medication for outpatient detoxification that is as effective as benzodiazepines in the short-term, and more effective in the protracted withdrawal period. Gabapentin (Neurontin) will be compared to a standard benzodiazepine, lorazepam (Ativan), for its effectiveness in treating alcohol withdrawal.
Interventions
- DRUG lorazepam (Ativan)
- DRUG gabapentin (Neurontin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00011297
The ClinicalTrials.gov registry entry for NCT00011297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lorazepam (Ativan) is the first listed.
NCT00011297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00011297 about?
NCT00011297 is a clinical study titled "Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal". This study will evaluate a safe and useful medication for outpatient detoxification that is as effective as benzodiazepines in the short-term, and more effective in the protracted withdrawal period. Gabapentin (Neurontin) will be compared to a standard benzodiazepine, lorazepam (Ativan), for its eff...
What is the current status of trial NCT00011297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00011297?
The interventions under investigation include: lorazepam (Ativan) (DRUG), gabapentin (Neurontin) (DRUG).
Who is sponsoring clinical trial NCT00011297?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.